



**World Health
Organization**

INN Working Document 14.349 rev. 2
ENGLISH ONLY
08/01/2015

***Pre-stems*:
Suffixes used in the selection of INN
November 2014***

Programme on International Nonproprietary Names (INN)

***Technologies Standards and Norms (TSN)
Regulation of Medicines and other health technologies (RHT)***

***World Health Organization,
Geneva***

© World Health Organization (2015) -This document is not issued to the general public, and all rights are reserved by the World Health Organization (WHO). The document may not be reviewed, abstracted, quoted, reproduced or translated, in part or in whole, without the prior written permission of WHO. No part of this document may be stored in a retrieval system or transmitted in any form or by any means - electronic, mechanical or other - without the prior written permission of WHO. The views expressed in documents by named authors are solely the responsibility of those authors.

*The prestems given have been flagged because they may be selected as official stems ("The use of stems in the selection of International Nonproprietary Names for Pharmaceutical Substances", 2013, WHO/EMP /RHT/TSN/2013.1). At present, they are made available for information and potential guidance to the applicants.

stem

definition

-*suffix*

-*infix-*

In bold: new pre-stems selected during the last Consultation.

In bold, underlined: newly selected stems.

- <i>algron</i>	α_1 -adrenoreceptor agonists
- <i>ampator</i>	α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor modulators
- <i>apt-</i>	aptamers, classical and mirror ones
- <u>asvir</u>	see <i>vir</i>
- <i>axomab</i>	see <i>mab</i>
- <i>berel</i>	estrogen receptor beta agonists
- <i>brutinib</i>	see <i>tinib</i>
- <i>caftor</i>	cystic fibrosis transmembrane regulator (CFTR) protein modulators
- <i>calcet/-calcet-</i>	calcium-sensing receptors (CaSR) agonists
- <i>camra</i>	intracellular adhesion molecule 1 (ICAM-1) derivatives
- <i>casan</i>	caspase converting enzyme inhibitors
- <i>caserin</i>	serotonin receptor agonists (mostly 5-HT ₂)
- <i>catib</i>	cathepsin inhibitors
- <i>citinib</i>	see <i>-tinib</i>
- <i>closporin</i>	ciclosporin derivatives
- <i>codar</i>	see <i>dar</i>
- <i>corat</i>	glucocorticoid receptor agonists
- <i>cridar</i>	see <i>dar</i>

<i>dar</i>	<i>drugs used in multidrug resistance</i>
- <i>cridar</i>	acridinecarboxamide derivatives
- <i>codar</i>	pipecolate derivatives
- <i>spodar</i>	ciclosporin D derivatives
- <i>degib</i>	SMO receptor antagonists
- <i>depsin</i>	depsipeptide derivatives
- <i>dil</i>	<i>vasodilators</i>
- <i>sudil</i>	Rho protein kinase inhibitors
- <i>domide</i>	antineoplastics, thalidomide derivatives
- <i>dustat</i>	see <i>stat</i>
- <i>ectedin</i>	ecteinascidin derivatives
- <i>espib</i>	heat shock protein (HSP) 90 inhibitors (other than <i>-mycin</i>), antineoplastics
- <i>estrant</i>	estrogen antagonists
- <i>fadine</i>	monoamine transport inhibitors
- <i>farnib</i>	farnesyl transferase inhibitors
- <u><i>fenacin</i></u>	<u>muscarinic receptor antagonists</u>
- <i>fibatide</i>	see <i>tide</i>
- <i>fulven</i>	antineoplastic, acylfulvene derivatives
- <i>gacestat</i>	see <i>-stat</i>
- <i>ganan</i>	antimicrobial, bactericidal permeability increasing polypeptides
- <i>gepant</i>	calcitonin gene-related peptide receptor antagonists
- <i>gapil</i>	neuronal apoptosis inhibitors, GAPDH
- <i>imepodib</i>	inosine monophosphate dehydrogenase inhibitors
- <i>imod</i>	immunomodulators, both stimulant/suppressive and stimulants
- <i>tolimod</i>	toll-like receptors (TLR) agonists

<i>-isant</i>	histamine H ₃ receptor antagonists
<i>-ixibat</i>	ileal bile acid transporter (IBAT) reabsorption inhibitors
<i>-kalner</i>	openers of calcium-activated (maxi-K) K ⁺ -channels
<i>-laner</i>	antagonists of GABA (gamma-aminobutyric acid)
<i>-leptin(e)</i>	leptin derivatives
<i>mab</i>	<i>monoclonal antibodies</i>
under species	
<i>-axo-</i>	rat-murine hybrid antibodies
under target	
<i>-gr(o)-</i>	skeletal muscle mass related growth factors and receptors
<i>-metinib</i>	see <i>tinib</i>
<i>-moren</i>	non-peptidic growth hormone secretagogues
<i>-nepag</i>	prostaglandins receptors agonists, non-prostanoids
<i>-nesib</i>	kinesin inhibitors
<i>-neurin</i>	neurotrophins
<i>nil</i>	<i>benzodiazepine receptor antagonists/agonists</i>
<i>-punil</i>	mitochondrial benzodiazepine receptor (MBR)- selective agonists also partial or inverse (purine derivatives)
<i>-opran</i>	μ-opioid receptors antagonists
<i>-orexant</i>	orexin receptor antagonists
<i>-osuran</i>	urotensin receptor antagonists
<i>-otilate</i>	hepatoprotectants, diisopropyl-1,3-dithiol-malonate derivatives
<i>-parantag</i>	antagonists of heparin and/or low-molecular weight heparins (LMWH)
<i>-paxar</i>	protease activated receptor type 1 (PAR1) antagonists
<i>-plasinin</i>	inhibitors of plasminogen activator inhibitors-type 1 (PAI-1)

-prazan	proton pump inhibitors, not dependent on acid activation
-prininim	nootropic agents, purine derivatives
-punil	see <i>nil</i>
<u>-ritide</u>	see <i>-tide</i>
-siban	oxytocin antagonists
-siran-	small interfering RNA
-spodar	see <i>dar</i>
-stat/-stat	<i>enzymes inhibitors</i>
-dustat	hypoxia inducible factor (HIF) prolyl hydroxylase inhibitors
-gacestat	gamma-secretase inhibitors
-stinel	NMDA receptor antagonist/agonists, glycine recognition site
-sudil	see <i>dil</i>
-sulind	antineoplastics, sulindac metabolites
-tegravir	see <i>vir</i>
-texafin	texaphyrin derivatives
-tide	<i>peptides and glycopeptides</i>
-fibatide	platelet aggregation inhibitor (GPIIb/IIIa receptor antagonist)
<u>-ritide</u>	<u>natriuretic peptides</u>
-tinib	<i>tyrosine kinase inhibitors</i>
-kininib	acromegaly/hyperparathyroidism, tyrosine kinase (Doxorubicin)

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/云报告?reportId=5_27598



云报告
https://www.yunbaogao.cn

云报告
https://www.yunbaogao.cn

云报告
https://www.yunbaogao.cn